Sun Pharma Explores US$10 Billion Funding Options for Organon Acquisition: Eurobonds, Loans in Focus

Dilip Shanghvi-led Sun Pharmaceutical Industries is evaluating multiple financing avenues to fund its proposed $11.75 billion acquisition of Organon & Co., as per news reports from Business Standard. The company is expected to raise close to $10 billion externally, while funding the remaining portion through internal accruals. This is expected to be one of the largest outbound deals by an Indian pharmaceutical firm.

Eurobonds, Bond Swaps Among Key Funding Options

According to reports, Sun Pharma is considering issuing Eurobonds via Organon’s European entity, a route that could offer tax efficiencies and access to global investors. Eurobonds allow issuers to raise capital in foreign currencies across international markets, making them a flexible financing instrument.

Another option under discussion is a bond swap arrangement, wherein existing Organon bondholders could exchange their holdings for Sun Pharma bonds. This move could benefit investors through improved credit quality, as Sun Pharma currently holds top-tier AAA ratings from domestic agencies. Such a structure may also help streamline the company’s debt profile post-acquisition.

Mix of Debt and Internal Accruals

The deal is likely to be funded through a combination of $9.25 billion to $9.75 billion in debt and $2 billion to $2.5 billion from internal accruals, as per news reports. Sun Pharma had a strong cash position of approximately $3.2 billion as of December 2025, providing a solid base for equity contribution.

In addition, the company is exploring offshore bank loans worth $3 billion to $4 billion. Global financial institutions including Citigroup Global Markets Asia, JPMorgan Chase, and MUFG Bank are reportedly advising on the financing structure.

Strategic Expansion and Synergy Potential

The acquisition is expected to significantly enhance Sun Pharma’s global footprint, leveraging Organon’s presence across 140 markets. Post-deal, the combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 global pharmaceutical companies.

Sun Pharma also sees potential cost synergies of up to $350 million over the next two to four years. The company aims to drive growth through improved patient access, product cross-launches, and a stronger in-licensing pipeline.

Read more: IndiGo Regains Operational Momentum in March 2026: OTP Crosses 88% in March After December Disruptions.

Conclusion

While the transaction is expected to close by early 2027, subject to regulatory and shareholder approvals, Sun Pharma’s multi-pronged funding strategy reflects a calculated approach to managing leverage and growth. If executed successfully, the Organon acquisition could mark a transformative phase in the company’s global expansion journey.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.